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Prolonged continuous intravenous infusion of the
dipeptide L-alanine- L-glutamine significantly
increases plasma glutamine and alanine without
elevating brain glutamate in patients with severe
traumatic brain injury
Mirjam Nägeli, Mario Fasshauer, Jutta Sommerfeld, Angela Fendel, Giovanna Brandi and John F Stover*
Abstract
Introduction: Low plasma glutamine levels are associated with worse clinical outcome. Intravenous glutamine
infusion dose- dependently increases plasma glutamine levels, thereby correcting hypoglutaminemia. Glutamine
may be transformed to glutamate which might limit its application at a higher dose in patients with severe
traumatic brain injury (TBI). To date, the optimal glutamine dose required to normalize plasma glutamine levels
without increasing plasma and cerebral glutamate has not yet been defined.
Methods: Changes in plasma and cerebral glutamine, alanine, and glutamate as well as indirect signs of metabolic
impairment reflected by increased intracranial pressure (ICP), lactate, lactate-to-pyruvate ratio, electroencephalogram
(EEG) activity were determined before, during, and after continuous intravenous infusion of 0.75 g L-alanine-L-glutamine
which was given either for 24 hours (group 1, n = 6) or 5 days (group 2, n = 6) in addition to regular enteral nutrition.
Lab values including nitrogen balance, urea and ammonia were determined daily.
Results: Continuous L-alanine-L-glutamine infusion significantly increased plasma and cerebral glutamine as well as
alanine levels, being mostly sustained during the 5 day infusion phase (plasma glutamine: from 295 ± 62 to 500 ±
145 μmol/ l; brain glutamine: from 183 ± 188 to 549 ± 120 μmol/ l; plasma alanine: from 327 ± 91 to 622 ± 182 μmol/ l;
brain alanine: from 48 ± 55 to 89 ± 129 μmol/ l; p < 0.05, ANOVA, post hoc Dunn’s test).
Plasma glutamate remained unchanged and cerebral glutamate was decreased without any signs of cerebral
impairment. Urea and ammonia were significantly increased within normal limits without signs of organ dysfunction
(urea: from 2.7 ± 1.6 to 5.5 ± 1.5 mmol/ l; ammonia: from 12 ± 6.3 to 26 ± 8.3 μmol/ l; p < 0.05, ANOVA, post hoc
Dunn’s test).
Conclusions: High dose L-alanine-L-glutamine infusion (0.75 g/ kg/ d up to 5 days) increased plasma and
brain glutamine and alanine levels. This was not associated with elevated glutamate or signs of potential
glutamate-mediated cerebral injury. The increased nitrogen load should be considered in patients with renal and
hepatic dysfunction.
Trial registration: Clinicaltrials.gov NCT02130674. Registered 5 April 2014
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Introduction
Low plasma glutamine is associated with increased mortal-
ity and aggravated functional impairment in critically ill
patients [1]. Thus, adequate substitution of the condition-
ally essential amino acid glutamine in critically ill patients
is strongly recommended by international societies with a
grade-A level of evidence [2,3]. Glutamine essentially sup-
ports protein synthesis, mitosis, muscle growth, immune
function, formation of the antioxidant glutathione, and
prevents apoptosis [4]. In addition, glutamine as a gluco-
neogenic and lipogenic precursor, increases cellular ener-
getic reserves, stimulates insulin release, and ameliorates
glucose metabolism under conditions of insulin resistance
in critically ill patients [4,5]. Glutamine administration
reduces infection-related increased morbidity [5-9],
decreases mortality during the intensive care phase [10,11],
shortens length of hospitalization [12,13], thereby substan-
tially reducing hospital costs [12-14]. The optimal dose,
however, still remains to be determined as concluded in
the SIGNET trial [15].
Plasma glutamine levels can be increased by enteral as
well as intravenous administration of glutamine [16].
However, metabolic conversion of glutamine increases
plasma glutamate levels especially during enteral glutamine
administration [16]. In patients suffering from a damaged
blood-brain barrier as encountered following severe trau-
matic brain injury (TBI) an increase in plasma glutamate is
feared to induce additional brain damage due to its excito-
toxic and edema-aggravating potential [17-19]. As shown
by Berg and colleagues [20], intravenous infusion of the
dipeptide L-alanine-L-glutamine administering 0.34 g glu-
tamine/kg limited to a 20-hour infusion period increased
plasma glutamine levels by 30% without elevating arterial
plasma or cerebral glutamate and without signs of cerebral
glutamate uptake in patients with severe head trauma
(Glasgow coma scale (GCS) score ≤8) [21]. In addition,
these results suggest that a glutamine dose exceeding
0.34 g/kg body weight might be required to normalize
decreased plasma glutamine levels in individual patients.
However, before a higher glutamine dose can be considered
safe in patients suffering from severe TBI, a glutamine-
dependent increase in cerebral glutamate and signs of
cerebral impairment must be excluded during prolonged
infusion of a higher glutamine dose. For this, we prospect-
ively investigated the effects of continuous intravenous
infusion of 0.5 g glutamine/kg/d (corresponding to
0.75 g/ kg/d Dipeptiven® = L-alanine-L-glutamine; 82 mg/
ml L-alanine, 134.6 mg/ ml L-glutamine; Fresenius Kabi,
Switzerland) for 24 hours (study 1, six patients) and 5 days
(study 2, six patients). Infusion-related analysis included
changes in arterial, jugular venous, and cerebral glutam-
ine, alanine, and glutamate levels as well as alterations in
brain glucose, lactate, and pyruvate. In addition, changes
in intracranial pressure (ICP), cerebral perfusion pressure
(CPP), brain tissue oxygenation (ptiO2), and electro-
encephalographic activity assessed by bispectral index
electroencephalogram (BIS EEG) technology were con-
tinuously recorded in patients with traumatic brain injury
(TBI) subjected to pharmacologic coma, using fentanyl
and midazolam.
Materials and methods
In study 1, a total of six patients were included to inves-
tigate the effects of 0.5 g glutamine/kg/d (Dipeptiven® =
L-alanine-L-glutamine: 82 mg/100 ml L-alanine and
134.6 mg/100 ml L-glutamine) continuously infused for
24 hours followed by a 24-hour observation period. In
study 2, a total of six patients were included to investigate
the effects of 0.5 g glutamine/kg/d (Dipeptiven® = L-ala-
nine-L-glutamine; 82 mg L-alanine, 134.6 mg L-glutamine)
continuously infused for 5 days followed by a 48-hour
observation period. The study protocol was approved by
the local ethics committee (Kantonale Ethikkommission
Zürich) and written informed consent was obtained by the
relatives of the patients.
Inclusion criteria
Patients suffering from severe TBI reflected by abnormal
neurologic status and pathologic neuroradiologic findings
were considered eligible when requiring pharmacologic
coma. Patients were only included if the different cathe-
ters (arterial and central venous lines, neuromonitoring
probes; vide infra) and triluminal jejunal feeding tube were
in place and functional for at least 12 hours before infus-
ing L-alanine-L-glutamine.
Patients who were anticipated to die within 48 hours
with abdominal injury, mass transfusion, renal or hepatic
impairment, requiring barbiturates to treat intracranial
hypertension, or receiving parenteral nutrition, and having
body weight below 50 kg or exceeding 100 kg were not
included.
Study protocol (study 1 and study 2)
Following admission to the trauma surgical ICU, all
patients were treated according to a standardized proto-
col as published previously [22,23]. For this, a BIS EEG
sensor was applied to guide analgesia and sedation
(Figure 1); a jugular venous catheter was inserted within
the first hour to guide ventilation and adjust analgesia/sed-
ation and CPP; after approximately 24 hours a control cra-
nial computed tomography (CT) scan was performed to
determine the site of insertion of the microdialysis (CMA
70, 10 mm membrane, CMA/ Microdialysis, Dallvägen 10,
Solna Sweden) and ptiO2 catheters (LICOX® IMC Oxygen
Catheter Micro Probe, Integra NeuroSciences, Plainsboro,
NJ, USA) to avoid penetrating frontal contusions, as these
would not yet be visible on the first CT and tend to de-
velop during the first 24 hours. Microdialysis, ptiO2 and
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temperature (LICOX® IMC Temperature Micro Probe;
Integra NeuroSciences) probes were inserted using a
triluminal bolt system (LICOX® IMC Bolt System,
Triple Lumen; Integra NeuroSciences). The patients
were fed enterally via a gastric feeding tube beginning
on the day of admission to the ICU, using Fresubin®
Energy fibre (Fresenius Kabi AG, Switzerland), containing
5.6 g protein/100 ml with 0.62 g glutamine/100 ml and
0.2 g alanine/100 ml with 1.5 kcal/ml. On the second
post-traumatic day a jejunal feeding tube was positioned
endoscopically by the gastroenterologists and enteral nu-
trition with Fresubin® Energy fibre was continued. None
of the patients received parenteral nutrition in addition to
the enteral nutrition. According to our standardized nu-
tritional protocol, enteral nutrition was begun within
12 hours after admission to the ICU, started at 10 ml/h
and increased by 10 ml/h in 6-hour intervals until reaching
the measured caloric requirement determined by indirect
calorimetry (Deltatrac™ II; Datex Instruments, Helsinki,
Finland). On the third post-traumatic day, patients in study
1 received L-alanine-L-glutamine at 0.5 g glutamine/kg/d
by continuous intravenous infusion for 24 hours, followed
by a 24-hour observation period. In study 2, aimed at
excluding an accumulation effect, L-alanine-L-glutamine
was continuously infused intravenously at 0.5 g glutam-
ine/kg/d starting on the third posttraumatic day lasting
for five days, followed by an additional 48-hour observa-
tion phase.
Cerebral microdialysis samples were measured hourly
to monitor metabolic alterations reflected by changes in
glucose, lactate, pyruvate, and glutamate. The remaining
volume was used to analyze changes in alanine, glutam-
ine, and glutamate by high performance liquid chroma-
tography (HPLC). In study 1, arterial and jugular venous
plasma samples were drawn at predefined time points
before, during (1, 4, 12, and 23 hours during the infusion
period), and after the infusion period (4, 12, and 23 hours
after the infusion). Indirect calorimetry was performed
before, during (8.0 and 23.5 hours), and after the infu-
sion period (6.0 and 23.5 hours).
In study 2, plasma arterial and jugular venous samples
were drawn at predefined time points before, during
(1, 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 hours),
and after the infusion period (4, 12, 23, and 48 hours after
the infusion). Indirect calorimetry was performed before,
during (12-hour intervals), and after the infusion period
(12-hour intervals). The results obtained during these
investigations were blinded to the clinicians and, thus, did
not influence clinical decision-making.
In both studies, predefined signs of glutamate-mediated
cerebral injury were actively sought by the study team
(JFS, MF, JS) with the aim of stopping the L-alanine-L-
day 1 3 6 7
L- alanine- L- glutamine infusion for 5 days
82
study 2
study 1
4 5 9 10
24 hours
control CT
insertion microdialysis and ptiO2
insertion jejunal feeding tube
admittance to ICU
BIS EEG- guided analgesia/ sedation
insertion jugular venous catheter
enteral nutrition
observation phase (study 2)
Infusion- related effects: 
cerebral microdialysis, ICP, CPP, 2, SjvO2, plasma values, indirect calorimetry, lab values
observation phase (study 1)
plasma samples
ptiO
Figure 1 Study protocol investigating the effects of continuously infusing L-alanine-L- glutamine (Dipeptiven® = L-alanine-L-glutamine;
82 mg L-alanine, 134.6 mg L-glutamine; 0.5 g glutamine/kg) for 24 hours (study 1) or 5 days (study 2) in six patients each suffering
from severe traumatic brain injury. The representative computed tomography (CT) scan shows the position of the microdialysis catheter and
intracranial pressure probe. ICP, intracranial pressure; CPP, cerebral perfusion pressure; ptiO2, brain tissue oxygen; SjvO2, jugular venous oxygen
saturation; BIS EEG, bispectral index electroencephalogram.
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glutamine infusion in case of cerebral metabolic impair-
ment reflected by elevated cerebral glutamate, increased
lactate and lactate/pyruvate ratio, decreased ptiO2, ele-
vated ICP, increased BIS EEG activity, and escalation in
therapeutic interventions, respectively. Here, the following
threshold values were defined a priori: a 2-fold increase in
plasma or cerebral glutamate associated with a 2-fold
increase in cerebral lactate or lactate/pyruvate ratio, or
ICP >20 mmHg, or SjvO2 < 60%, or arterial-jugular ven-
ous oxygen difference < -0.2, or BIS EEG >40, or a more
aggressive treatment approach.
Investigated parameters
Bedside analysis of glutamate was performed enzymati-
cally using the bedside ISCUSFlex Microdialysis Analyzer
(CMA/Microdialysis, Dalvägen 10, Solna, Sweden) to
guide possible termination of L-alanine L-glutamine infu-
sion. In addition, metabolic parameters, that is, glucose,
lactate, pyruvate, and calculated lactate/pyruvate ratio
were also determined enzymatically. Glutamine, glutam-
ate, and alanine were determined in arterial and jugular
venous plasma and cerebral microdialysis by HPLC.
ICP, CPP, BIS EEG were recorded continuously using
the LabPilot™ software (CMA/Microdialysis, Dalvägen 10,
Solna, Sweden). ptiO2 (LICOX® IMC Oxygen Catheter
Micro Probe) and brain temperature (LICOX® IMC Tem-
perature Micro Probe) (Integra NeuroSciences) were recor-
ded continuously using the LabPilot™ software (CMA/
Microdialysis, Dalvägen 10, Solna, Sweden). Indirect
calorimetry was performed using the Deltatrac™ II (Datex
Intrsuments, Helsinki, Finland), which also allowed us to
determine the respiratory quotient (RQ).
Routine laboratory values were determined once daily
assessing changes in lymphocytes, creatinine, urea, and
ammonia. Nitrogen balance was calculated by subtract-
ing urinary nitrogen determined in urine collected over
24 hours from the daily nitrogen intake (enteral nutrition
plus L-alanine-L-glutamine infusion); possible nitrogen
loss via, for example, skin and stool were not considered.
HPLC analysis of amino acids
Plasma samples were drawn using commercially available
pre-heparinized syringes (safe PICO Aspirator, Radiom-
eter, Copenhagen, Radiometer Medical ApS, Åkadevej 21,
DK- 2700 Brønshøj, Denmark). Following centrifugation
at 4°C and 10,000 rpm for 10 minutes (HETTICH Zentri-
fugen Universal 30 F/ RF, HETTICH AG, 8806 Bäch,
Switzerland) samples were deproteinized with acetonitrile
(plasma 1:7, microdialysate 1:3). Following centrifugation
the supernatant was frozen at -80˚C until further analysis.
Following unthawing, samples were vortexed and spiked
with the internal standard norvaline (NVA), centrifuged,
and applied to a vacuum manifold system (Multi-well
Filter Plate Vacuum Manifold and Accessories for 96-well
Filter Plates, Pall Corporation, USA, Port Washington,
NY 11050) using a vacuum of 77.5 mmHg for 15 seconds.
Thereafter the samples were transferred to a cooled auto-
sampler maintained at 4˚C. Before automated injection,
samples were incubated with ortho-phthaldialdehyde
(OPA) (1:1) for 1 minute. After injection, a stepped gradi-
ent at a flow rate of 1.5 ml/min was applied (buffer B: 0, 0,
30, 50, 100, 0, 0% at 0, 0.8, 12, 16, 16.2, and 17 minutes)
with a total run time of 18 minutes. HPLC was linked
to a fluorescence detector (Agilent HPLC 1100 Serie, Agi-
lent Technologies AG, Basel, Switzerland) set at 340 nm
(excitation) and 450 nm (emission wavelength). Stationary
phase was a ZORBAX Eclipse AAA column (4.6 × 75 mm,
3.5-μm particle size) (Agilent Technologies AG). The fol-
lowing mobile phases were used: buffer A: 5.5 g sodium
dihydrogen phosphate anhydrous (H2NaO4P) + 1 l Aqua
HPLC (purified, filtered distilled water) and buffer B:
450 ml acetonitrile + 450 ml methanol + 100 ml Aqua
HPLC (sodium dihydrogen phosphate anhydrous, aceto-
nitrile, and methanol were purchased from Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland).
A standard mixture of the amino acids (AA) analyzed
as an external standard was also spiked using the
same internal standard (NVA) as in the plasma and
microdialysis samples. OPA, AA and NVA standards
were purchased from Agilent Technologies AG, Basel,
Switzerland.
Standardized intensive care treatment following severe
traumatic brain injury
All patients were treated on our ICU according to a
standardized protocol as published previously [22,23]
with integrated extended neuromonitoring [24]. Routine
treatment and decision-making were not influenced by
the present investigations. Continuously infused midazo-
lam (Dormicum®) and fentanyl (Sintenyl®) were tapered
according to ICP and BIS EEG values, maintaining ICP
values <15 mmHg and BIS EEG values between 20 and
40. Volume and norepinephrine were adjusted to main-
tain CPP values between 60 and 90 mm Hg. Transcra-
nial color-coded Duplex sonography was performed
daily to guide CPP (including volume management) and
ventilator settings (paCO2 levels) according to changes
in flow velocity determined in the middle cerebral artery
[25]. Ventilation, oxygenation, CPP, and blood transfu-
sions were guided by maintaining ptiO2 > 15 mmHg.
Statistical analysis
Results of the different parameters assessed at the prede-
fined time points in the individual patients were pre-
sented as box plots. Cerebral glutamine, alanine, and
glutamate values were determined by HPLC in hourly
collected samples pooled in 4-hour blocks resulting in
six values to calculate a median per day per patient; the
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box plots represent six daily median values for the six
patients in study 1 and six patients in study 2. In study
2, the daily medians are compiled in one box plot after
having excluded significant differences during the pro-
longed infusion phase. Statistical differences in changes
before, during and after L-alanine-L-glutamine infusion
and between the study groups were evaluated by one-
way analysis of variance followed by Dunn’s multiple
comparison test. Differences were rated significant at
P <0.05.
Results
Demographic data
The investigated twelve patients in the two separate studies
were comparable presenting with mixed lesions, predomin-
antly consisting of contusions combined with hemispheric
edema. In study 1, the two female and four male patients
suffered from severe TBI (median Abbreviated Injury Score
(AIS) 4, range 3 to 5) with a median age of 30 (range 19 to
45) and a median body mass index of 21 kg/m2 (range 19
to 23) required prolonged analgesia and sedation with
extended neuromonitoring for a median of 13 days (range
7 to 34 days). Microdialysis and ptiO2/ temperature probes
were inserted in the more severely injured hemisphere with
two in the left frontal and four in the right frontal lobe,
respectively. Patients survived with a median extended
Glasgow Outcome Score (GOS) of 6 (range 5 to 8) at
12 months following posttraumatic neurorehabilitation.
In study 2, the two female and four male patients
suffered from severe TBI (median AIS 4, range 3 to 5)
with a median age of 28 years (range 17 to 42) and a
median body mass index of 23 kg/m2 (range 21 to 26)
required prolonged analgesia and sedation with extended
neuromonitoring for a median of 14 days (range 9 to
37 days). Neuromonitoring probes were inserted in the
more severely injured hemisphere with three in the left
frontal and three in the right frontal lobe, respectively.
Insertion of probes did not induce any additional tissue
damage as revealed by subsequent CT imaging. Patients
survived with a median extended Glasgow Outcome
Score (GOS) of 6 (range 5 to 8) at 12 months following
post-traumatic neurorehabilitation.
Amount of infused L-alanine-L-glutamine and enteral
nutrition
For the administration of 0.5 g glutamine/kg/d a median
of 13 ml L-alanine-L-glutamine (Dipeptiven®) was infused
per hour during the 24-hour (study 1) and 5-day (study 2)
group, respectively (Table 1). This resulted in a cumulative
median amount of 312 ml per day (range 216 to 360 ml)
(study 1) and 1,560 ml for 5 days (range 1,080 to
1,800 ml) (study 2).
Enteral nutrition was continuously applied without
any interruptions, resulting in an overall median amount
of 45 ml per hour before, during, and after the L-alanine-
L-glutamine infusion phase (studies 1 and 2) (Table 1).
Changes in plasma glutamine, alanine, and glutamate
levels
Continuous infusion of L-alanine-L-glutamine significantly
and reversibly increased plasma glutamine levels from
295 ± 62 μmol/L to 395 ± 175 μmol/L during the 24-hour
phase and to 500 ± 145 μmol/L during the 5-day infusion
phase, reaching the highest values during the 5-day infu-
sion period (Figure 2).
During the 24-hour and 5-day infusion phase plasma
alanine was significantly and reversibly increased from
327 ± 91 μmol/L reaching highest values during the
5-day infusion period (622 ± 182 μmol/L) (Figure 3).
Following the 24-hour infusion phase, plasma alanine
returned to baseline levels whereas plasma alanine
levels remained significantly increased following the 5-day
infusion phase (Figure 3). Plasma glutamate levels re-
mained unchanged during the entire study period (before
infusion, 62 ± 18; during infusion, 54 ± 22; after infusion,
57 ± 19 μmol/L), irrespective of infusion duration.
Overall, there were no significant differences between
arterial and jugular venous alanine, glutamine, and
glutamate levels (data not shown).
Changes in cerebral glutamine, alanine, and glutamate
levels
During the 24-hour infusion phase (study 1) cerebral
glutamine (before infusion, 529 ± 99; during infusion,
549 ± 120; after infusion, 532 ± 110 μmol/L), alanine
(before infusion, 82 ± 69; during infusion, 89 ± 90;
after infusion, 77 ± 78 μmol/L), and glutamate (before
infusion, 12 ± 11; during infusion, 5 ± 10; after infusion,
6 ± 9 μmol/L) remained unchanged.
In study 2, prolonged L-alanine-L-glutamine infusion
was associated with significantly increased cerebral gluta-
mine after the infusion phase (Figure 4), whereas cerebral
alanine was significantly increased during and after the
infusion phase (Figure 5). Cerebral glutamate was sig-
nificantly decreased during and after the infusion phase
(Figure 6).
Changes in cerebral glucose, lactate, lactate-to-pyruvate
ratio
Extracellular cerebral glucose, lactate, and lactate-to-
pyruvate ratio were not influenced by the L-alanine-
L-glutamine infusion, irrespective of infusion duration
(Table 1).
Changes in neuromonitoring and sedation
During the 24-hour (study 1) and 5-day infusion phase
(study 2) ICP, CPP, and ptiO2 remained unchanged
(Table 1). Sedation was slowly reduced on days 8 and 9
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after TBI, resulting in significantly increased BIS values
compared to baseline values (Table 1).
Changes in caloric requirement, respiratory quotient,
laboratory values, and calculated nitrogen balance
Compared to baseline values caloric requirement (kcal/d)
was significantly increased over time, reaching the highest
values after the 5-day infusion phase, that is, on days 8
and 9 after TBI (Table 1). Calculated RQ remained
unchanged. Hepatic and renal function, determined by
changes in aspartate aminotransferase (GOT), alanine ami-
notransferase (GPT), and creatinine, respectively, remained
normal (Table 1).
Urea and ammonia levels were significantly increased
during the 5-day L-alanine-L-glutamine infusion phase,
which persisted during the post-infusion observation
phase (Table 1), remaining well below predefined patho-
logic threshold values of 15 mmol/L (urea) and 50 μmol/L
(ammonia), respectively. During the 24-hour infusion
phase the trend in increased urea and ammonia did not
reach statistical significance (urea (median) before infu-
sion, 2.2; during infusion, 3.3; after infusion, 2.9 mmol/L,
and ammonia (median) before infusion, 12.8; during infu-
sion, 21.7; after infusion, 18.2 μmol/L).
The calculated nitrogen balance was positive at all time
points and was not changed during the 24-hour and
Table 1 Changes in enteral nutrition, neuromonitoring, caloric requirement, and laboratory values before, during, and
after prolonged continuous L-alanine-L-glutamine infusion
Before infusion During infusion After infusion
Enteral nutrition and L-alanine-L-glutamine infusion
Enteral nutrition (ml/h) 42 ± 8, 30, 62 45 ± 11, 25, 60 47 ± 15, 30, 90
Calories (kcal/d) 1512 ± 288, 1,080, 2,232 1620 ± 396, 900, 2,160 1692 ± 540, 1,080, 3,240
L-alanine-L-glutamine (ml/h) – 13 ± 2, 9, 15 –
Neuromonitoring
ICP (mmHg) 11 ± 4, 4, 18 9 ± 5, 0, 40 9 ± 6, 0, 25
CPP (mmHg) 78 ± 6, 71, 90 79 ± 7, 60, 98 80 ± 8, 56, 110
Brain temperature (°C) 35.1 ± 0.2, 34.8, 35.4 35.4 ± 0.26, 34.6, 36 35.5 ± 0.5, 34.5, 37
ptiO2 (mmHg) 23 ± 11, 10, 40 29 ± 9, 15, 65 27 ± 8, 11, 57
BIS 33 ± 8, 20, 45 35 ± 12, 10, 94 42 ± 18, 10, 89*
Brain glucose (mM) 0.76 ± 0.99; 0.5, 3.5 1.1 ± 1.1; 0.6, 4.6 0.68 ± 1.0; 0.4, 6,5
Brain lactate (mM) 2.2 ± 3.5; 0.8, 11 3.8 ± 1.6; 0.5, 8.5 3.2 ± 1.7; 0.5, 9.3
Brain lactate-to-pyruvate ratio 14 ± 25; 2.4, 88 14 ± 23; 2, 136 9 ± 22; 3, 300
Caloric requirement
Kcal 1,830 ± 193; 1,440, 1,940 1,945 ± 320; 1,480, 2,810 2,115 ± 353; 1,830, 2,830*
RQ 0.84 ± 0.07; 0.76, 0.94 0.84 ± 0.05; 0.76, 0.96 0.83 ± 0.07;0.72, 0.9
Laboratory values
CRP 149 ± 79, 1.3, 203 109 ± 78; 25, 371 76 ± 69; 12, 269
Fibrinogen 4 ± 1.7; 1.7, 7.1 6.2 ± 1.5; 2.3, 8.5 6.5 ± 1.8; 2.2, 11.6
Albumin (g/L) 23 ± 4; 13, 29 22 ± 4; 14, 31 21 ± 5; 14, 33
Blood urea (mmol/L) 2.7 ± 1.6; 1.2, 7 5.5 ± 1.5; 1.6, 9.7* 5.1 ± 2.2; 2.2, 10.5
Ammonia (μmol/L) 12 ± 6.3; 6, 25 26 ± 8.3; 10, 51* 26 ± 8.4; 4, 34*
Creatinine (μmol/L) 68 ± 23; 53, 126 66 ± 16; 42, 122 68 ± 17; 45, 99
GOT (U/ml) 44 ± 61, 15, 206 42 ± 40; 13, 165 60 ± 53; 13, 191
GPT (U/ml) 20 ± 50; 11, 141 19 ± 64, 10, 172 18 ± 58, 12, 158
Urine urea (mmol/L) 74 ± 56; 40, 203 136 ± 85; 31, 398 117 ± 53; 36, 215
Nitrogen balance (g/d) 8 ± 3.6; 5.9, 10.7 10 ± 1.6; 6.9, 11 8.5 ± 3.3; 6, 16.5
Lymphocytes (10-3/μl) 0.9 ± 0.4; 0.37, 1.58 0.9 ± 0.3; 0.38, 1.59 1.0 ± 0.7; 0.72, 3.17
Sedation
Midazolam (mg/h) 90 ± 20; 60, 110 90 ± 20; 60, 110 70 ± 20; 40, 90*
Nitrogen balance was calculated based on administered nitrogen from protein and amino acids minus nitrogen in urinary urea without including other potential
losses via, for example, skin and stool. Results are shown as median ± standard deviation; range. *P <0.001 analysis of variance and post hoc Dunn’s test. ICP, CPP,
BIS, ptiO2, RQ, respiratory quotient; CRP, C-reactive protein; GOT, aspartate aminotransferase; GPT, alanine aminotransferase.
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5-day L-alanine-L-glutamine infusion period (Table 1).
The lymphocyte count was not influenced by the 24-
hour or the 5-day L-alanine-L-glutamine infusion phase,
respectively (Table 1).
Discussion
Following severe TBI continuous intravenous infusion of
the dipeptide L-alanine-L-glutamine at 0.5 g glutamine/
kg/d and 0.25 g alanine/kg/d significantly and reversibly
increased plasma glutamine and alanine concentrations.
The increase in plasma glutamine was not associated
with elevated plasma or cerebral glutamate or any indir-
ect signs of secondary brain damage reflected by signs of
metabolic impairment, increased ICP, decreased ptiO2,
or sustained pharmacologic intervention to reduce ICP.
Markedly elevated plasma glutamine and alanine were
associated with significantly increased cerebral glutamine
and alanine levels.
Plasma glutamine and alanine in critically ill patients
Stress and inflammation as well as hormonal changes
substantially influence plasma glutamine and alanine
pathways to fuel energy-consuming processes [26,27].
Sustained glutamine consumption depletes the muscular
glutamine storage and decreases plasma glutamine. Com-
pared to healthy volunteers as published by Stegink et al.,
[28] and Pouw et al., [29] plasma glutamine was signifi-
cantly decreased in the critically ill patients suffering from
severe TBI, who were investigated in the current study.
Hypoglutaminemia as presently shown is in line with the
changes seen following, for example, elective surgery [30],
neurotrauma [31,32], burn injury [33], sepsis [34], renal
insufficiency [35], and chronic pulmonary disease [29].
Hypoglutaminemia, in turn, negatively influences clinical
development in critically ill patients, aggravates severity of
illness [1], and is associated with increased mortality and
morbidity [1], thereby presenting a rationale for corrective
strategies.
Contrary to the obvious hypoglutaminemia, baseline
plasma alanine determined before L-alanine-L-glutamine
infusion was comparable to healthy individuals [28,29]
and not reduced following TBI [32]. Normal plasma ala-
nine levels could reflect well-functioning endogenous regu-
latory processes or successful supply via enteral nutrition,
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Figure 2 Changes in plasma glutamine during the 24-hour and 5-day L-alanine-L-glutamine infusion phase. During the infusion phase
plasma glutamine was significantly and reversibly increased compared to baseline values (*P <0.001, analysis of variance, post hoc Dunn’s test)
which was sustained during the 5-day compared to the 24-hour infusion phase (+P <0.001).
Figure 3 Changes in plasma alanine during the 24-hour and 5-day L- alanine-L-glutamine infusion phase. During the infusion phase
plasma alanine was significantly increased compared to baseline values (*p <0.001, analysis of variance, post hoc Dunn’s test), which was mostly
sustained during the 5-day infusion phase compared to the 24-hour infusion (+P <0.001). Although elevated plasma alanine levels reached
baseline values following the 24-hour infusion phase, plasma alanine levels remained increased following the 5-day infusion phase.
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as all patients had been successfully fed enterally before
starting the L-alanine-L-glutamine infusion.
Impact of prolonged L–alanine-L-glutamine infusion on
brain parameters
Brain alanine and glutamine levels were only significantly
increased if L-alanine-L-glutamine was infused for 5 days
compared to 24 hours. This suggests that prolonged infu-
sion is required to influence brain levels. The persistent
increase in brain glutamine and alanine levels could either
be induced by the infusion itself or by downstream alter-
ations with reduced consumption of glutamine and ala-
nine. Perhaps this pattern reflects time-dependent healing
following TBI. However, this cannot be assessed by this
study because no control group had been included.
Infusing 0.5 g glutamine/kg/d for 24 hours and 5 days
did not influence measured metabolic parameters and
most importantly did not increase brain glutamate levels.
In addition, this infusion regimen did not induce cerebral
glutamate release as arterio-jugular venous difference
remained unchanged. In fact, cerebral glutamate showed a
continuous significant decrease over time. Whether this
decrease was induced and supported by the present infu-
sion protocol cannot be determined as we did not include
a control group. Indirect signs of glutamate-mediated cell
injury were absent as reflected by unchanged cerebral glu-
cose, lactate, lactate-to-pyruvate ratio, ICP, CPP, BIS EEG,
and absent treatment escalation. This is in line with the
results provided by Berg and coworkers in patients with
severe head trauma (GCS ≤8) [20,21]. Contrary to the
published cerebral glutamine release [21] arterio-jugular
venous glutamine differences remained unchanged in the
present study. This discrepancy could stem from differ-
ences in overall management, including depth of sedation,
choice of sedative drugs, cooling, degree of injury, and
type of brain lesions. Another possible influence could be
the type of nutrition. Whereas Berg and colleagues com-
bined the dipeptide alanine-glutamine with parenteral
nutrition, we added alanine-glutamine to enteral nutrition
based on the fact that enteral nutrition alone does not
Figure 4 Changes in cerebral glutamine determined by
cerebral microdialysis during the 5-day L-alanine-L-glutamine
infusion phase. Cerebral glutamine remained unchanged during the
infusion phase and showed a significant increase after the 5-day
infusion period (*P <0.001, analysis of variance, post hoc Dunn’s test).
Figure 5 Changes in cerebral alanine determined by cerebral
microdialysis during the 5-day L-alanine-L-glutamine infusion
phase. Compared to baseline values cerebral alanine was
significantly increased during the infusion phase and remained
significantly elevated during the 48-hour post infusion observation
phase (*P <0.001, analysis of variance, post hoc Dunn’s test).
Figure 6 Changes in cerebral glutamate determined by
cerebral microdialysis during the 5 day L-alanine-L-glutamine
infusion phase. Compared to baseline values cerebral glutamate
was significantly decreased during the infusion phase and remained
significantly reduced during the 48-hour post infusion observation
phase (*P <0.001, analysis of variance, post hoc Dunn’s test).
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increase plasma glutamine comparable to its intravenous
infusion. Whether the simultaneously infused amino acids
in the parenteral nutrition additionally and differentially
influences brain metabolism, and specifically glutamine-
mediated changes, remains to be investigated in a
separate study.
The present investigations extend the available know-
ledge as we investigated a higher dose, that is, 0.5 g glu-
tamine/kg versus 0.34 g/kg and a longer duration, that is,
24 hours and 5 days versus 20 hours [20,21]. The obtained
data show that intravenous infusion of glutamine at a dose
higher than currently recommended (0.5 versus 0.34 g/kg/d)
does not increase cerebral glutamate or induce glutamate-
mediated cerebral injury. Thus, this dose and the longer
duration appear to be safe in patients with severe TBI.
Infusing a higher dose of alanine, that is, 0.25 g
alanine/kg/d for 24 hours and 5 days compared to 0.17 g
alanine/kg/d for 20 hours [20,21] significantly increased
cerebral alanine levels with unchanged arterio-jugular
venous difference. Whether the significant and persisting
increase in cerebral alanine contributed to the significantly
decreased cerebral glutamate by fueling gluconeogene-
sis, thereby sparing glutamate and glutamine as energy-
delivering compounds [36,37] or influencing ammonia
and lactate transfer [38] cannot be answered by the pre-
sent study. Increased cerebral alanine levels were not asso-
ciated with a decrease in BIS EEG values or reduction in
administered midazolam dose, which questions its role in
neuronal inhibition under the conditions of the present
study design [39].
Which glutamine and alanine dose and which duration of
infusion could be optimal?
Contrary to previous investigations, a higher glutamine
and alanine dose was infused in the current study, that is,
0.75 g versus 0.5 g L-alanine-L-glutamine/kg/d with the
aim of normalizing and maintaining normalized plasma
glutamine levels. Albeit a significant increase in plasma
glutamine even this higher dose, that is, 0.5 g versus
0.35 g glutamine/kg/d failed to completely normalize
plasma glutamine levels in all patients. This strongly sug-
gests a sustained requirement. Whether this can be met
by infusing an even higher glutamine dose in these pa-
tients is currently unclear. As shown in non-TBI patients
glutamine must be infused at 0.57 or 0.86 g/kg/d to suc-
cessfully normalize plasma glutamine levels [40].
Plasma alanine was also significantly increased by the
currently investigated protocol. Baseline plasma alanine
values had already been normal. Thus, the necessity to
further increase plasma alanine seems questionable. How-
ever, the present study does not allow us to determine
potential positive intracellular effects in terms of alanine-
mediated sustained protein synthesis and decreased pro-
tein degradation to define required plasma alanine levels.
Duration of L-glutamine-L-alanine infusion determines
persistence of elevated plasma levels. In this context,
plasma glutamine returned to baseline values within
30 minutes or 8 hours following a 30-minute versus a
4-hour infusion, respectively [41,42]. This might explain
the significantly increased plasma glutamine and alanine
levels during the 5-day versus the 24-hour infusion
period observed in the present study. As reflected by
the significantly decreased plasma glutamine and ala-
nine levels during the post-infusion period, glutamine
and alanine did not accumulate. This is in line with
previous reports [43].
Clinical investigations with a larger number of patients
are needed to define the optimal dose and duration. The
present investigation was not designed to assess the
impact of L-alanine-L-glutamine infusion on clinical
outcome in this specific population of critically ill TBI
patients. The present results could aid in defining the
required dose and duration in future clinical trials. The
results and the glutamine dose used in the recently
published large-scale clinical trials do not provide clear
answers as to which glutamine dose is to be used. In the
SIGNET trial [15], glutamine is discussed as most likely
having been too low. In the REDOXS study, the total glu-
tamine dose from simultaneous enteral and intravenous
administration might have been too high in patients suf-
fering from multi-organ failure with unresolved shock,
renal failure, and insufficient nutrition [44].
Side effects of prolonged infusion of a higher glutamine
and alanine dose
In line with amino acid-induced ammoniagenesis and
ureagenesis [45-48] the presently investigated patients
showed increased ammonia and urea levels during L-
alanine-L-glutamine infusion compared to baseline values,
as they received an average total nitrogen load of 19.7 g/d
(median enteral nitrogen load 9.7 g/d, median parenteral
nitrogen load from L-alanine-L-glutamine infusion 10 g/d).
The elevated urea and ammonia levels did not reach
worrisome levels and were not associated with signs
of neurologic and metabolic deterioration as ICP re-
mained unchanged, and glutamate was significantly de-
creased in the face of stable brain metabolism reflected by
unchanged cerebral lactate and lactate-to-pyruvate ratio.
Apparently, critically ill patients, even with normal hepatic
function according to laboratory values and medical his-
tory, respond differently to protein load compared to
healthy individuals who can tolerate a glutamine load of
0.65 g glutamine/kg/d without increased plasma ammonia
levels [49]. As the increased blood ammonia and urea
levels were well within the normal range this metabolic
response is not considered a safety concern. The currently
investigated patients did not show any signs of hep-
atic or renal dysfunction. Thus, the investigated dose
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and duration cannot be extrapolated to all patients.
The primary aim of these investigations was to deter-
mine pharmacodynamic changes. In this context, the
missing control group does not allow us to differenti-
ate influences on ammoniagenesis and ureagenesis at-
tributable to nutrition or alanyl-glutamine infusion.
Limitations of the present study
The low number of patients and the chosen study design
without having included a control group does not allow
us to recommend the investigated dose and duration in
all patients. The presently investigated patients comprise
a well-defined subpopulation, which does not allow us
to generalize as these patients did not suffer from any
additional organ dysfunction apart from brain injury, did
not require dialysis or hemofiltration, and had a well-
functioning gastrointestinal tract receiving enteral nutri-
tion according to the individually determined caloric
requirement.
Conclusions
Low plasma glutamine levels were significantly and revers-
ibly increased by continuous intravenous infusion of
0.75 g L-alanine-L-glutamine, reaching highest plasma
glutamine and alanine levels during the 5-day infusion
phase. Infusion of L-alanine-L-glutamine for 5 days was
required to significantly increase brain glutamine and ala-
nine levels compared to the 24-hour infusion phase. The
absent increase in glutamate as well as absent indirect
signs of glutamate-mediated cerebral injury under-
score the reported safety of 1) infusing L-alanine-L-
glutamine and 2) using the investigated dose in patients
with severe TBI. To normalize plasma glutamine levels
higher glutamine amounts exceeding 0.5 g/kg/d might be
required.
Key messages
 Continuous intravenous infusion of L-alanine-L-
glutamine at 0.75 g/kg/d for 5 days significantly
increased plasma as well as cerebral glutamine and
alanine levels
 This increase in plasma glutamine was not
associated with elevated plasma and cerebral
glutamate, and cerebral glutamate release.
 The continuous infusion of L-alanine-L-glutamine
at 0.75/g/kg/d for 24 hours significantly
increased plasma glutamine and alanine levels
without influencing cerebral glutamine and
alanine levels.
 Overall, continuous intravenous infusion of a
higher L-alanine-L-glutamine dose (0.75 g/kg/d)
for up to 5 days was not associated with signs of
glutamate-mediated cerebral injury.
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